630067-06-0 Usage
Uses
Used in Coordination Chemistry:
1,10-Phenanthroline-5-carboxylic acid is used as a ligand for the formation of metal complexes, leveraging its ability to chelate with metal ions, which is crucial in various chemical and biological processes.
Used in Anticancer Research:
In the field of oncology, 1,10-Phenanthroline-5-carboxylic acid is used as a potential anticancer agent, being investigated for its capacity to interact with biological targets and exhibit antitumor activity.
Used in Inhibition of Metalloenzymes:
1,10-Phenanthroline-5-carboxylic acid serves as an inhibitor of metalloenzymes, which are enzymes that require metal ions for their catalytic activity. Its use in this capacity can have implications in the regulation of enzymatic processes.
Used in Research and Development of Fluorescent Probes for Metal Ions:
1,10-Phenanthroline-5-carboxylic acid is utilized in the development of fluorescent probes designed to detect and measure the presence of metal ions, which is vital for understanding metal ion dynamics in biological systems.
Used in Study of DNA-Binding Proteins:
1,10-Phenanthroline-5-carboxylic acid is applied in research aimed at understanding the interactions between DNA and proteins, which is fundamental to the comprehension of genetic regulation and the development of new therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 630067-06-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,0,0,6 and 7 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 630067-06:
(8*6)+(7*3)+(6*0)+(5*0)+(4*6)+(3*7)+(2*0)+(1*6)=120
120 % 10 = 0
So 630067-06-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H8N2O2/c16-13(17)10-7-8-3-1-5-14-11(8)12-9(10)4-2-6-15-12/h1-7H,(H,16,17)
630067-06-0Relevant articles and documents
ANTI-CANCER LEUCIN-RICH PEPTIDES AND USES THEREOF
-
Page/Page column 11, (2021/04/17)
The invention relates to a pharmaceutically acceptable composition for use in the treatment of cancer, the composition comprising one or more peptides having a sequence comprising the motif GLLxLLxLLLxAAG, wherein x is independently selected from arginine (R), histidine (H), lysine (K), aspartic acid (D) or glutamic acid (E), and one or more pharmaceutically acceptable excipients. The invention also relates to the peptides of the pharmaceutically acceptable composition, a kit comprising the pharmaceutically acceptable composition, nucleotides encoding the peptides and vectors expressing the peptides.